STOCK TITAN
  1. Home
  2. Sec-filings
  3. GRCE
  4. [D] Grace Therapeutics, Inc. SEC Filing

Grace Therapeutics (GRCE) completes $9.99M Rule 506(b) private equity raise

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
D

Rhea-AI Filing Summary

Grace Therapeutics, Inc., a Delaware biotechnology corporation with no revenues, filed a notice of an exempt securities offering. The company is relying on Rule 506(b) of Regulation D for a private equity offering. It reports a total amount sold of $9,999,998 in equity securities, with $0 remaining to be sold, and a first sale date of August 4, 2026. Craig-Hallum Capital Group is listed under sales compensation, and the company discloses $0 in finders' fees.

Positive

  • None.

Negative

  • None.
Total Amount Sold $9,999,998 USD Equity securities sold in exempt offering
Total Remaining to be Sold $0 USD Remaining amount under this exempt offering
Issuer Revenues No Revenues Issuer size classification at time of offering
Finders' Fees $0 USD Reported finders' fees for the offering
Date of First Sale 2026-08-04 Start of sales in the exempt offering
Exemption Relied Upon Rule 506(b) Regulation D exemption for the private offering
Rule 506(b) regulatory
"X | Rule 506(b) | Rule 506(c) | Securities Act Section 4(a)(5)"
Rule 506(b) is a U.S. securities exemption that lets companies sell shares or debt privately without full public registration, provided sales are primarily to accredited investors, up to 35 non‑accredited but financially knowledgeable buyers, and there is no public advertising or solicitation. It matters to investors because offerings under 506(b) usually include less public disclosure than registered securities—like buying from a private seller rather than a retail store—so buyers must do more of their own fact‑checking and rely on their financial sophistication.
Regulation D regulatory
"if the issuer is claiming a Regulation D exemption for the offering"
Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.
covered securities regulatory
"if the securities that are the subject of this Form D are "covered securities""
Investment Company Act of 1940 regulatory
"Is the issuer registered as an investment company under the Investment Company Act of 1940?"
A U.S. federal law that sets the rulebook for pooled investment vehicles such as mutual funds, exchange-traded funds and similar money managers, requiring them to register with regulators, disclose holdings and fees, limit conflicts of interest, and follow governance standards. It matters to investors because these protections and transparency rules act like a referee and scoreboard, helping people compare funds, trust that managers follow fair practices, and spot hidden costs or risks.
National Securities Markets Improvement Act of 1996 regulatory
"Section 102(a) of the National Securities Markets Improvement Act of 1996"
A federal law that harmonizes and simplifies securities regulation by reducing conflicting state rules and giving the U.S. Securities and Exchange Commission primary authority over many aspects of securities offerings and investment adviser registration. Think of it as replacing a patchwork of local traffic laws with one consistent highway code — it lowers compliance costs and makes transactions more predictable, while investors should watch how it balances streamlined markets against the level of state-level protections.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

FAQ

What type of securities is Grace Therapeutics, Inc. (GRCE) offering?
Grace Therapeutics, Inc. is offering equity securities in a private placement relying on Rule 506(b) of Regulation D, as disclosed in its exempt offering notice.

How much has Grace Therapeutics, Inc. (GRCE) sold in its exempt offering?
Grace Therapeutics, Inc. reports a total amount sold of $9,999,998 in its exempt equity offering, with $0 remaining to be sold under this notice.

When did the Grace Therapeutics, Inc. (GRCE) offering first close a sale?
The first sale in Grace Therapeutics, Inc.’s exempt equity offering occurred on August 4, 2026, according to the disclosed date of first sale.

What exemption is Grace Therapeutics, Inc. (GRCE) using for this securities offering?
Grace Therapeutics, Inc. is relying on Rule 506(b) under Regulation D of the Securities Act for its private equity offering, claiming an exemption from registration.

Does Grace Therapeutics, Inc. (GRCE) have revenues at the time of this offering?
Grace Therapeutics, Inc. identifies its issuer size as having no revenues, indicating it is a pre-revenue biotechnology company at the time of this exempt offering.

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Intentional misstatements or omissions of fact constitute federal criminal violations. See 18 U.S.C. 1001.

FORM D

Notice of Exempt Offering of Securities
OMB APPROVAL
OMB Number: 3235-0076
Estimated average burden
hours per response: 4.00

1. Issuer's Identity

CIK (Filer ID Number) Previous Names
None
Entity Type
0001444192
Acasti Pharma Inc.
X Corporation
Limited Partnership
Limited Liability Company
General Partnership
Business Trust
Other (Specify)

Name of Issuer
Grace Therapeutics, Inc.
Jurisdiction of Incorporation/Organization
DELAWARE
Year of Incorporation/Organization
X Over Five Years Ago
Within Last Five Years (Specify Year)
Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer
Grace Therapeutics, Inc.
Street Address 1 Street Address 2
103 CARNEGIE CENTER SUITE 300
City State/Province/Country ZIP/PostalCode Phone Number of Issuer
PRINCETON NEW JERSEY 08540 609-322-1602

3. Related Persons

Last Name First Name Middle Name
Kohli Prashant
Street Address 1 Street Address 2
103 Carnegie Center Suite 300
City State/Province/Country ZIP/PostalCode
Princeton NEW JERSEY 08540
Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Chief Executive Officer
Last Name First Name Middle Name
Kavuru Vimal
Street Address 1 Street Address 2
103 Carnegie Center Suite 300
City State/Province/Country ZIP/PostalCode
Princeton NEW JERSEY 08540
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
DelAversano Robert J.
Street Address 1 Street Address 2
103 Carnegie Center Suite 300
City State/Province/Country ZIP/PostalCode
Princeton NEW JERSEY 08540
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Vice President, Finance, Principal Financial Officer and Principal Accounting Officer
Last Name First Name Middle Name
Davis A. Brian
Street Address 1 Street Address 2
103 Carnegie Center Suite 300
City State/Province/Country ZIP/PostalCode
Princeton NEW JERSEY 08540
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
Kottayil S. George
Street Address 1 Street Address 2
103 Carnegie Center Suite 300
City State/Province/Country ZIP/PostalCode
Princeton NEW JERSEY 08540
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
Neugeboren Edward
Street Address 1 Street Address 2
103 Carnegie Center Suite 300
City State/Province/Country ZIP/PostalCode
Princeton NEW JERSEY 08540
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
Macdonald Dr. R. Loch
Street Address 1 Street Address 2
103 Carnegie Center Suite 300
City State/Province/Country ZIP/PostalCode
Princeton NEW JERSEY 08540
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Chief Medical Officer
Last Name First Name Middle Name
Kumar Amresh
Street Address 1 Street Address 2
103 Carnegie Center Suite 300
City State/Province/Country ZIP/PostalCode
Princeton NEW JERSEY 08540
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

VP of Program Management

4. Industry Group

Agriculture
Banking & Financial Services
Commercial Banking
Insurance
Investing
Investment Banking
Pooled Investment Fund
Is the issuer registered as
an investment company under
the Investment Company
Act of 1940?
Yes No
Other Banking & Financial Services
Business Services
Energy
Coal Mining
Electric Utilities
Energy Conservation
Environmental Services
Oil & Gas
Other Energy
Health Care
Biotechnology
Health Insurance
Hospitals & Physicians
X Pharmaceuticals
Other Health Care
Manufacturing
Real Estate
Commercial
Construction
REITS & Finance
Residential
Other Real Estate
Retailing
Restaurants
Technology
Computers
Telecommunications
Other Technology
Travel
Airlines & Airports
Lodging & Conventions
Tourism & Travel Services
Other Travel
Other

5. Issuer Size

Revenue Range OR Aggregate Net Asset Value Range
X No Revenues No Aggregate Net Asset Value
$1 - $1,000,000 $1 - $5,000,000
$1,000,001 - $5,000,000 $5,000,001 - $25,000,000
$5,000,001 - $25,000,000 $25,000,001 - $50,000,000
$25,000,001 - $100,000,000 $50,000,001 - $100,000,000
Over $100,000,000 Over $100,000,000
Decline to Disclose Decline to Disclose
Not Applicable Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))
Rule 504 (b)(1)(i)
Rule 504 (b)(1)(ii)
Rule 504 (b)(1)(iii)
X Rule 506(b)
Rule 506(c)
Securities Act Section 4(a)(5)
Investment Company Act Section 3(c)
Section 3(c)(1) Section 3(c)(9)
Section 3(c)(2) Section 3(c)(10)
Section 3(c)(3) Section 3(c)(11)
Section 3(c)(4) Section 3(c)(12)
Section 3(c)(5) Section 3(c)(13)
Section 3(c)(6) Section 3(c)(14)
Section 3(c)(7)

7. Type of Filing

X New Notice Date of First Sale 2026-08-04 First Sale Yet to Occur
Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year?
Yes X No

9. Type(s) of Securities Offered (select all that apply)

X Equity Pooled Investment Fund Interests
Debt Tenant-in-Common Securities
Option, Warrant or Other Right to Acquire Another Security Mineral Property Securities
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor $1 USD

12. Sales Compensation

Recipient
Recipient CRD Number None
Craig-Hallum Capital Group 000121395
(Associated) Broker or Dealer X None
(Associated) Broker or Dealer CRD Number X None
None None
Street Address 1 Street Address 2
323 N. Washington Ave. Suite 300
City State/Province/Country ZIP/Postal Code
Minneapolis MINNESOTA 55401
State(s) of Solicitation (select all that apply)
Check "All States" or check individual States		 All States
X Foreign/non-US
MASSACHUSETTS
NEW YORK
TEXAS
DELAWARE
CONNECTICUT

13. Offering and Sales Amounts

Total Offering Amount $9,999,998 USD
or Indefinite
Total Amount Sold $9,999,998 USD
Total Remaining to be Sold $0 USD
or Indefinite

Clarification of Response (if Necessary):

14. Investors

 Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
9

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions $560,000 USD
Estimate
Finders' Fees $0 USD
Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

$0 USD
Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:
  • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
  • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
  • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer Signature Name of Signer Title Date
Grace Therapeutics, Inc. /s/ Prashant Kohli Prashant Kohli CEO 2026-08-10

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.

Source: View Original Filing on SEC EDGAR